Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and AnHeart Therapeutics Co., Ltd., a clinical stage oncology company focused on underserved patients in global markets, today jointly announce an exclusive license agreement for the co-development and commercialization of AnHeart's lead drug candidate, taletrectinib – a next-generation tyrosine kinase inhibitor (TKI) designed to effectively target ROS1 and NTRK - in Greater China, including mainland China, Hong Kong, S.A.R., China, Macau, S.A.R., China and Taiwan, China.
Under the terms of the agreement, Innovent will obtain exclusive rights to co-develop and commercialize taletrectinib in Greater China. AnHeart will continue to be responsible for the development of taletrectinib up to regulatory approval in mainland China and for supplying taletrectinib for both developmental and commercial purposes in Greater China. Innovent has the right to co-develop taletrectinib in Hong Kong, S.A.R., China, Macau, S.A.R., China and Taiwan, China up to regulatory approval.
According to the agreement, AnHeart will receive an upfront payment, R&D fees, and potential milestone payments totaling USD189 million in addition to tiered royalties based on annual net sales of taletrectinib in Greater China.
Taletrectinib is currently undergoing three phase 2 studies, including (i) the phase 2 study for first line treatment of TKI-naive and second line treatment of TKI-pretreated ROS1-positive non-small cell lung cancer (NSCLC) in China, (ii) the phase 2 study for NTRK-positive solid tumors in China, and (iii) the phase 2 study for first line and second line treatment of ROS1-positive NSCLC globally.
"We are excited to collaborate with Innovent, a leading biopharmaceutical company which has demonstrated outstanding development and commercialization capabilities, to commercialize taletrectinib in greater China," said Jerry Junyuan Wang, PhD, CEO and co-founder of AnHeart. "Following the first commercial partnership in Korea we entered into with NewG Lab in July 2020, our collaboration with Innovent further advances our mission to accelerate global patient access to taletrectinib upon approval."
Dr. Yong Jun Liu, president of Innovent, stated, "We are very pleased to enter a collaboration with AnHeart. We have been impressed with our partner's capability to advance the global development of taletrectinib and we are excited to help bring taletrectinib to patients in Greater China. This collaboration further strengthens our position in oncology by adding a late stage and potential best-in-class targeted therapy into our portfolio. At the same time, it further proves that Innovent is an ideal partner for biopharmaceutical companies in terms of accelerating development and commercialization progress."
About Taletrectinib
Taletrectinib is an investigational next-generation TKI designed to effectively target ROS1 and NTRK with potential to treat TKI-naïve or pretreated patients. ROS1 rearrangement is estimated to be an oncogenic driver in approximately 2 to 3 percent of patients with advanced NSCLC, and NTRK fusion is estimated to be an oncogenic driver in approximately 0.5 percent of patients across multiple advanced solid tumors. There's very limited approved therapy available for advanced ROS1-positive lung cancer patients and NTRK-positive cancer patients in Greater China. After treatment with existing therapies, most patients eventually acquire resistance for which there are significant unmet medical needs globally.
AnHeart has observed a 100% overall response rate (ORR) by investigator review from 11 ROS1-positive NSCLC patients who were not previously treated with a tyrosine kinase inhibitor (TKI) utilizing a January 15, 2021 data cut-off from the Phase 2 portion of the ongoing taletrectinib TRUST trial. Taletrectinib was also generally well-tolerated. These data demonstrate the potential for taletrectinib to be a best-in-class treatment. Data with more patient from first line (ROS1 TKI naive) and second line (ROS1 TKI pretreated) will be published during the 2021 ASCO.
(All Rights Reserved)